Thoughts on today's announcement: - Today’s n
Post# of 72440
(Total Views: 853)
Posted On: 09/15/2020 11:16:32 AM
Thoughts on today's announcement:
- Today’s news is outstanding in that it will get Brilacidin additional attention with the scientific community and investment community.
- Leo will move forward with a solo Brilacidin human trial initially.
- The fact that the RBL ran the Remdesivir tests indicate that the government is interested in improving their current investment and a combo trial could take place very quickly.
- This combo number further solidifies the odds of IPIX getting grant funding.
- The current Administration has been looking for a “cure” for CV19. Once this 100% effectiveness number is communicated (any day) a UUUGE press conference proclamation would give IPIX immediate worldwide attention.
- The rapid deployment of Brilacidin can take place without IPIX needing a partner in the U.S. An international BP distribution channel partnership may take place.
- IMO any discussion of an IPIX buyout is very pre-mature. The quickest path to market for Brilacidin is to deploy the planned Phase 2 CV19 human trial with a rapid advancement to Emergency Use Authorization. This is the best path for treating the CV19 pandemic and is also the best path for IPIX investors. IPIX does not need a buyout or even a BP partnership for this to happen. Once Brilacidin is approved by the FDA for CV19 the value of the Brilacidin franchise vastly increases. Every Brilacidin instance approved including B-IBD UC and B-OM will greatly add to Brilacidin’s franchise value.
- Today is one of 8-10 IPIX PR’s that could take place in the next 2 months. Great things are happening at IPIX and the science will win.
- Each announcement will put more pressure on the criminals that control IPIX SP. One of the upcoming IPIX PR’s or a government press conference will gap IPIX SP to several dollars along with multiple trading days of record volume which will signal the criminals losing their grip.
- How much is the Gold Standard Treatment for CV19 worth? See post #65303
- Today’s news is outstanding in that it will get Brilacidin additional attention with the scientific community and investment community.
- Leo will move forward with a solo Brilacidin human trial initially.
- The fact that the RBL ran the Remdesivir tests indicate that the government is interested in improving their current investment and a combo trial could take place very quickly.
- This combo number further solidifies the odds of IPIX getting grant funding.
- The current Administration has been looking for a “cure” for CV19. Once this 100% effectiveness number is communicated (any day) a UUUGE press conference proclamation would give IPIX immediate worldwide attention.
- The rapid deployment of Brilacidin can take place without IPIX needing a partner in the U.S. An international BP distribution channel partnership may take place.
- IMO any discussion of an IPIX buyout is very pre-mature. The quickest path to market for Brilacidin is to deploy the planned Phase 2 CV19 human trial with a rapid advancement to Emergency Use Authorization. This is the best path for treating the CV19 pandemic and is also the best path for IPIX investors. IPIX does not need a buyout or even a BP partnership for this to happen. Once Brilacidin is approved by the FDA for CV19 the value of the Brilacidin franchise vastly increases. Every Brilacidin instance approved including B-IBD UC and B-OM will greatly add to Brilacidin’s franchise value.
- Today is one of 8-10 IPIX PR’s that could take place in the next 2 months. Great things are happening at IPIX and the science will win.
- Each announcement will put more pressure on the criminals that control IPIX SP. One of the upcoming IPIX PR’s or a government press conference will gap IPIX SP to several dollars along with multiple trading days of record volume which will signal the criminals losing their grip.
- How much is the Gold Standard Treatment for CV19 worth? See post #65303
(16)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼